Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Melanie Senior
Experiments are underway to solve pharma’s well-documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up different kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in healthcare.
GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.
Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.
Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.
Berg compares diseased and healthy tissue to drive drug discovery.
When it comes to drug pricing, one size certainly doesn’t fit all. Biopharma firms need to devise and design appropriate pricing and commercial strategies for payers, a group of customers that don’t all care about the same things and, in some cases, whose needs may be diametrically opposed.